SG10201909209RA - Nucleic acid-cationic polymer compositions and methods of making and using the same - Google Patents

Nucleic acid-cationic polymer compositions and methods of making and using the same

Info

Publication number
SG10201909209RA
SG10201909209RA SG10201909209RA SG10201909209RA SG 10201909209R A SG10201909209R A SG 10201909209RA SG 10201909209R A SG10201909209R A SG 10201909209RA SG 10201909209R A SG10201909209R A SG 10201909209RA
Authority
SG
Singapore
Prior art keywords
making
methods
nucleic acid
same
cationic polymer
Prior art date
Application number
Inventor
Abraham Hochberg
Jennifer Gallula
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of SG10201909209RA publication Critical patent/SG10201909209RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are pre-lyophilized compositions containing a nucleic acid, a cationic polymer, and a carbohydrate. Also provided are lyophilized compositions of matter and reconstituted compositions as well as methods of making using the same for treating tumors in patients. No Figure.
SG10201909209R 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same SG10201909209RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL23864315 2015-05-05

Publications (1)

Publication Number Publication Date
SG10201909209RA true SG10201909209RA (en) 2019-11-28

Family

ID=56134418

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909209R SG10201909209RA (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same
SG11201708760PA SG11201708760PA (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201708760PA SG11201708760PA (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Country Status (14)

Country Link
US (2) US20180154023A1 (en)
EP (1) EP3291799A1 (en)
JP (2) JP2018515479A (en)
KR (1) KR20180015145A (en)
CN (1) CN107735079A (en)
AU (1) AU2016258326A1 (en)
BR (1) BR112017023788A2 (en)
CA (1) CA2984879A1 (en)
IL (1) IL255254A0 (en)
MX (1) MX2017014060A (en)
PH (1) PH12017502216A1 (en)
RU (1) RU2017140065A (en)
SG (2) SG10201909209RA (en)
WO (1) WO2016178233A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201909209RA (en) * 2015-05-05 2019-11-28 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
DE102017003004A1 (en) 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Cationic polymers with D-fructose substituents
EP3448363B1 (en) 2017-05-17 2022-05-11 Highlight Therapeutics, S.L. Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
WO2020165656A1 (en) * 2019-02-11 2020-08-20 Excellgene S.A. Novel eukaryotic cell transfection systems and related methods
CN111363761A (en) * 2020-03-17 2020-07-03 苏州吉恒基因科技有限公司 Method for promoting AAV-mediated gene expression by using cationic polymer DNA complex
WO2021222133A1 (en) * 2020-04-27 2021-11-04 Juno Therapeutics, Inc. Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity
US20240245720A1 (en) 2021-05-25 2024-07-25 Ramot At Tel-Aviv University Ltd. Compositions comprising extracellular vesicles and an active agent and uses thereof
CN113501889A (en) * 2021-07-06 2021-10-15 郑州大学 Preparation method and application of pseudo-ginseng polysaccharide cationic derivative
CN116549626A (en) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 Nucleic acid-loaded lipid nanoparticle freeze-dried preparation and preparation method and application thereof
CN114762731B (en) * 2022-05-16 2024-08-23 常州大学 Method for prolonging storage time of gene medicine under mild condition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2722506B1 (en) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa COMPOSITION CONTAINING NUCLEIC ACIDS, PREPARATION AND USES
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
JP2009508516A (en) 2005-09-22 2009-03-05 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム Nucleic acid constructs, pharmaceutical compositions, and methods of use thereof for cancer treatment
EP2111450A2 (en) 2007-01-16 2009-10-28 Yissum Research Development Company of the Hebrew University of Jerusalem Nucleic acid constructs and methods for specific silencing of h19
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
CN107049965A (en) * 2007-08-06 2017-08-18 Clsn实验室股份有限公司 Nucleic acid lipopolymer compositions
ES2394129T3 (en) 2007-10-25 2013-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Constructs Containing Multiple Expression Cassettes for Cancer Therapy
CN102202693A (en) * 2008-09-03 2011-09-28 森尼斯科技术公司 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
DE102009006606A1 (en) * 2009-01-29 2010-08-05 Philipps-Universität Marburg Non-viral transfection agent
SG10201909209RA (en) * 2015-05-05 2019-11-28 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same

Also Published As

Publication number Publication date
US20200138977A1 (en) 2020-05-07
JP2021130671A (en) 2021-09-09
WO2016178233A1 (en) 2016-11-10
CN107735079A (en) 2018-02-23
PH12017502216A1 (en) 2018-06-11
RU2017140065A (en) 2019-06-05
EP3291799A1 (en) 2018-03-14
MX2017014060A (en) 2018-07-06
KR20180015145A (en) 2018-02-12
JP2018515479A (en) 2018-06-14
AU2016258326A1 (en) 2017-11-23
US20180154023A1 (en) 2018-06-07
BR112017023788A2 (en) 2018-10-16
CA2984879A1 (en) 2016-11-10
SG11201708760PA (en) 2017-11-29
RU2017140065A3 (en) 2019-09-27
IL255254A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
GB2557123A (en) Modified cells and methods of therapy
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
CA2956871C (en) Compounds active towards bromodomains
MX2018002990A (en) Use of pasteurized akkermansia for treating metabolic disorders.
MX2016002544A (en) Compounds useful as immunomodulators.
MX2017011997A (en) Piperazine carbamates and methods of making and using same.
GB2541571A (en) Pharmaceutical compositions
MX2014011134A (en) Carbamate compounds and of making and using same.
MX2015009106A (en) Solid solution compositions and use in severe pain.
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX356755B (en) Fumigillol type compounds and methods of making and using same.
PH12015501088A1 (en) Dimeric compounds
MA40460A (en) Lysosomal targeting and uses thereof
MX2018014718A (en) Compounds and their use for reducing uric acid levels.
MX2019015676A (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug.
BR112017022022A8 (en) ARENAVIRUSES FOR USE IN THE TREATMENT AND/OR PREVENTION OF TUMORS AND METHOD FOR THE PRODUCTION OF ARENAVIRUSES WITH (ENPROVED) TUMOR REGRESSION PROPERTIES
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2017012553A (en) Spirocyclic compounds.
MY200161A (en) Bacteria for targeting tumors and treating cancer
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
JOP20190164B1 (en) Compositions and methods for treating farber disease
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
WO2019016597A3 (en) Synthetic proteins and therapeutic uses thereof